Neuronetics (STIM) Reports Q3 Loss, Misses Revenue Estimates

分组1 - Neuronetics reported a quarterly loss of $0.13 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, but an improvement from a loss of $0.29 per share a year ago, indicating an earnings surprise of -18.18% [1] - The company posted revenues of $37.3 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 2.21%, but showing significant growth from $18.53 million in the same quarter last year [2] - Neuronetics shares have increased approximately 72.1% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] 分组2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for Neuronetics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $42.37 million, and for the current fiscal year, it is -$0.56 on revenues of $150.79 million [7] 分组3 - The Medical - Instruments industry, to which Neuronetics belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]